A list of puns related to "Kidney transplantation"
2.2. Organ-Targeted Therapy
The widespread use of machine perfusion for organ storage and of the in situ perfu- sion of organs from DCD donors have revived interest in treatment strategies aimed at preventing DGF by treating the renal graft ex vivo. Hypothermic perfusion machines are currently the most widely used. They are portable machines that keep low temperature (4–10 ◦C), deliver a pulsatile flow, and optionally provide oxygenation (oxygenated ver- sus non-oxygenated machine perfusions). A meta-analysis has shown that hypothermic machine perfusion is superior to static cold storage in preventing DGF in deceased donor kidney transplantation [57]. This is true for both DBD and DCD kidneys. As kidneys from DCD donors have a higher overall DGF rate, fewer perfusions are needed to prevent one episode of DGF (7 vs. 14 in DBD kidneys) [57]. However, in the hypothermic state, cells from the graft have dampened metabolic activity. Interest has grown around normothermic machine perfusion, in which the perfusion temperature is between 35 and 37 ◦C [58]. This technique of organ preservation facilitates restoration of cellular metabolism, reviv- ing the organ ex vivo, which eventually resumes its normal physiological functions [59]. Therefore, theoretically, normothermic machine perfusion enables the graft to respond to pharmacological treatment.
Among the most promising pharmacological treatments that may be administered to the graft via machine perfusion to prevent DGF and fibrosis is cell therapy based on multipotent adult progenitor cells (MAPC) [60]. Multipotent adult progenitor cells possess immunomodulatory properties which could prove beneficial in minimizing subsequent ischemia reperfusion injury. Thompson et al. investigated the potential reconditioning capability of ex vivo administration of MAPC in a pre-clinical normothermic machine per- fusion model in kidney [61]. MAPC-treated kidneys showed improvement in urine output, decreased expression of the kidney injury biomarker NGAL, and improved microvascular perfusion [61].
https://doi.org/10.3390/jcm10071484
××××××××××××××××××××
Patent coverage expanding into Europe.
IMPROVING ORGANS FOR TRANSPLANTATION - Published.
https://worldwide.espacenet.com/publicationDetails/originalDocument?flavour=trueFull&locale=en_EP&FT=D&CC=EP&NR=3795159A1&KC=A1&popup=true
American Journal of Transplantation Accepted Articles - Great News
https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.16100
Please note that this site uses cookies to personalise content and adverts, to provide social media features, and to analyse web traffic. Click here for more information.